Companies › Trogenix
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TGX-007 AAV-mediated dual-payload gene therapy delivering HSV-tk and IL-12 for tumor cell killing | HSV-TK, IL12 | Phase 1 | Glioblastoma (GBM) | Mar 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07346144 | TGX-007 | Phase 1 | Glioblastoma (GBM) | Oncology | Mar 2030 |
Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Sonnet BioTherapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.